Quince Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 11, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 11, 2025

QNCX$31.73+8.1%Stored close · as of Oct 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Operating expenses:
Research and development	$6,553	$4,147	$14,698	$7,849
General and administrative	3,342	4,695	8,131	9,666
Goodwill impairment charge	—	17,130	—	17,130
Fair value adjustment for contingent consideration	532	2,220	2,456	4,765
Total operating expenses	10,427	28,192	25,285	39,410
Loss from operations	(10,427)	(28,192)	(25,285)	(39,410)
Fair value adjustment for long-term debt	(501)	(415)	(945)	(803)
Fair value adjustment for warrants	(4,464)	—	(4,464)	—
Warrant issuance costs	(872)	—	(872)	—
Interest income	311	823	717	1,710
Other income (expense), net	(29)	91	(116)	(308)
Net loss before income tax expense	(15,982)	(27,693)	(30,965)	(38,811)
Income tax expense	(67)	(36)	(114)	(67)
Net loss	(16,049)	(27,729)	(31,079)	(38,878)
Other comprehensive loss:
Foreign currency translation adjustments	4,216	(726)	6,261	(1,955)
Unrealized gain (loss) on available-for-sale securities	(17)	(12)	(70)	(5)
Total comprehensive loss	$(11,850)	$(28,467)	$(24,888)	$(40,838)
Net loss per share - basic and diluted	$(0.34)	$(0.64)	$(0.69)	$(0.90)
Weighted average shares of common stock outstanding - basic and diluted	46,686,239	43,096,374	45,314,234	43,053,351

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.